BioCentury | Sep 21, 2015
Clinical News

IV TRC105: Phase II data

...complete response. The patient has completed 7 cycles of treatment and levels of beta chorionic gonadotropin (hCG...
BioCentury | Sep 19, 2015
Clinical News

Tracon gains on single patient study

...Indonesia. Tracon said IV TRC105 in combination with Avastin bevacizumab normalized levels of beta-human chorionic gonadotropin (beta-hCG...
BioCentury | Jun 9, 2014
Company News

Strand Life Sciences Pvt. Ltd., HealthCare Global Enterprises Ltd. deal

...Strand partnered with HealthCare Global Enterprises (HCG) to provide personalized genomics services for oncology to hospitals...
...and HCG's Triesta Sciences unit. Strand declined to disclose financial terms for the partnership, and HCG...
BioCentury | Feb 25, 2013
Company News

NexGen Medical Systems Inc, Stem Cell Therapeutics deal

...to disclose details, while NexGen could not be reached. NTx-265, a regimen of human chorionic gonadotropin (hCG...
...alfa (EPO), has completed Phase II testing for ischemic stroke. NTx-428, also a combination of hCG...
BioCentury | Aug 8, 2011
Clinical News

BHCG-VAC: Phase II discontinued

...cisplatin and gemcitabine alone prior to surgical resection in about 30 patients with newly diagnosed hCG-beta...
...Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: BHCG-VAC (CDX-1307) (formerly MDX-1307) Business: Cancer Molecular target: Chorionic gonadotropin (hCG...
...composed of a mannose receptor-specific human antibody conjugated to the beta chain of human chorionic gonadotropin (hCG...
BioCentury | May 9, 2011
Clinical News

NTx-428: Phase IIa started

...TSX-V:SSS), Calgary, Alberta Product: NTx-428 Business: Inflammation Molecular target: NA Description: Combination of human chorionic gonadotropin (hCG...
BioCentury | Sep 20, 2010
Clinical News

NTx-265: Additional Phase IIb data

...Calgary, Alberta Product: NTx-265 Business: Neurology Molecular target: Not applicable Description: Regimen of human chorionic gonadotropin (hCG...
BioCentury | Jul 5, 2010
Company News

Stem Cell Therapeutics neurology news

...a "definitive explanation" for the large placebo effect. In May, the regimen of human chorionic gonadotropin (hCG...
BioCentury | May 31, 2010
Clinical News

NTx-265: Phase IIb data

...Calgary, Alberta Product: NTx-265 Business: Neurology Molecular target: Not applicable Description: Regimen of human chorionic gonadotropin (hCG...
BioCentury | May 24, 2010
Clinical News

CDX-1307: Phase II started

...Celldex began a U.S. Phase II trial in about 60 patients with newly diagnosed hCG-beta expressing...
...NASDAQ:CLDX), Needam, Mass. Product: CDX-1307 ( BHCG-VAC , MDX-1307 ) Business: Cancer Molecular target: Chorionic gonadotropin (hCG...
...composed of a mannose receptor-specific human antibody conjugated to the beta chain of human chorionic gonadotropin (hCG...
Items per page:
1 - 10 of 103